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We welcome the comment by Feller and colleagues [1]
about our study on ovarian cancer epidemiology and treat-
ment in Switzerland [2]. Their comment contributes to a
much-needed discussion on the strengths and limitations of
the various data sources available for epidemiological re-
search in Switzerland.
Our study estimated the incidence of ovarian cancer based
on a hospital registry covering all inpatient care episodes.
This mandatory registry was first introduced in 1998 by
the Federal Office of Statistics with the primary goal of
epidemiological surveillance [3] and allows patients to be
tracked over time and across treatment sites. We identified
incident ovarian cancer patients based on a C56 (malignant
neoplasm of the ovary) main diagnosis and by applying a
preceding ovarian cancer event-free period of 6 years. In
comparison with data of the National Institute for Cancer
Epidemiology and Registration (NICER), we found a sim-
ilar slight decline in age-adjusted incidence of ovarian can-
cer between 2004 and 2012, but at a substantially higher
level (+35%).
Feller and colleagues have probed our results with two
approaches. Firstly, they replicated our incidence estima-
tion based on hospital registry data for ovarian cancer and
five other selected cancers sites for the period 2011–2014.
Their estimates for ovarian cancer are in line with our re-
sults. However, the differences between NICER rates and
hospital registry-based rates differ substantially in mag-
nitude and sign of the difference. Secondly, they verified
the accuracy of diagnostic coding of ovarian cancer cases
in the hospital registry with related pathology reports and
found numerous coding errors. After eliminating these
coding errors their estimate of hospital registry-based inci-
dence was much more in line with NICER rates.
These results are quite puzzling, both because of the het-
erogeneous differences between NICER and hospital reg-
istry-based cancer incidence estimates and because of the
substantial coding errors detected. The diagnostic coding
in the hospital registry is, for example, repeatedly evalu-
ated by auditors, as diagnostic coding is also relevant for
the SwissDRG hospital reimbursement scheme. We see
an urgent need to better understand the causes of these
discrepancies. The hospital registry has several strengths,
which are complementary to the strengths of the NICER
cancer registry, as it not only covers all inpatient-treated
diseases but also allows monitoring of patients over sub-
sequent inpatient stays. Combining these important data
sources might substantially contribute to a better under-
standing of cancer epidemiology, treatment and health out-
comes in Switzerland.
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